Intrauterine testosterone exposure and male depression in adulthood

• Conditions: F31; F32; F33; Bipolar affective disorder; Depressive episode; Recurrent depressive disorder

• Registration Number: DRKS00015291
• Lead Sponsor: niversitätsklinikum Erlangen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-11-27
• Study Start: 2020-01-06
• Results First Posted: 2021-09-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 339

Inclusion Criteria

Written informed consent, body mass index > 18.5 and < 35 kg/m². Groups of depressed patients: moderate or severe depression (ICD-10: F31.3, F31.4, F32.1, F32.2, F33.1, F33.2), admission to in-patient treatment no more than 4 days prior to day of study inclusion. Separation between depressed patients with male depression and depressed patients without male depression according to the Gotland Male Depression Scale

Exclusion Criteria

Schizophrenia, schizotypal, delusional, & other non-mood psychotic disorders (F2). Group control subjects without depression: Regular intake of psychotropic drugs or sex hormones (with the exception of contraceptives), current psychiatric diagnosis according to ICD-10, liftetime psychiatric in-patient treatment, outpatient consultation or treatment due to a psychiatric disorder during the previous ten years

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Second-to-fourth finger length ratio (2D:4D) at study inclusion assessed by hand scans

Secondary Outcome Measures

Name	Time	Method
Age at pubertal onset, transient-evoked otoacoustic emissions, handedness; total, free, and bioavailable levels of blood testosterone, dihydrotestosterone, estradiol, and progesterone; alcohol consumption (AUDIT), tobacco consumption (Fagerström test), impulsivity (I-8), body mass index, personality (Inventar klinischer Persönlichkeitsakzentuierungen)